Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
gptkb:brand |
| gptkbp:approves |
gptkb:2020
gptkb:FDA |
| gptkbp:clinical_trial |
Phase 2
|
| gptkbp:dosage_form |
gptkb:capsule
|
| gptkbp:effective_date |
FDA approved
|
| gptkbp:formulation |
oral solution
|
| https://www.w3.org/2000/01/rdf-schema#label |
Koselugo
|
| gptkbp:indication |
pediatric patients
|
| gptkbp:ingredients |
gptkb:selumetinib
|
| gptkbp:is_used_for |
treatment of neurofibromatosis type 1
|
| gptkbp:manufacturer |
gptkb:Astra_Zeneca
|
| gptkbp:marketed_as |
gptkb:United_States
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:used_for |
treatment of neurofibromatosis type 1
|
| gptkbp:bfsParent |
gptkb:selumetinib
|
| gptkbp:bfsLayer |
7
|